Glomerulosclerosis, Focal Segmental Clinical Trial
Official title:
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
This is a single-arm, multicenter, open-label Phase II, proof-of-mechanism study to evaluate the efficacy, safety, tolerability and pharmacokinetics of losmapimod in approximately 21 subjects with primary (idiopathic) focal segmental glomerulosclerosis (FSGS) and substantive proteinuria as indicated by a Urinary protein/creatinine Up/c ratio >=2 gram/gram (g/g) or 24 hr urine protein >=2 g/day. Losmapimod will be orally administered twice daily over a 24-week treatment phase followed by a 12-week follow-up for safety and relapse assessments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00098020 -
Podocyte Retinoids
|
Phase 2 | |
| Completed |
NCT04340362 -
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
|
Phase 2 | |
| Terminated |
NCT04387448 -
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
|
Phase 2 | |
| Terminated |
NCT04235621 -
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
|
||
| Recruiting |
NCT01209000 -
Nephrotic Syndrome Study Network
|
||
| Recruiting |
NCT05505500 -
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
|
||
| Recruiting |
NCT03949972 -
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
|